Pfizer (NYSE:PFE) Trading Down 1.5% - What's Next?

Pfizer Inc. (NYSE:PFE - Get Free Report) shares dropped 1.5% during trading on Wednesday . The company traded as low as $25.52 and last traded at $25.60. Approximately 11,083,563 shares traded hands during trading, a decline of 72% from the average daily volume of 39,512,609 shares. The stock had previously closed at $25.99.

Analyst Ratings Changes

PFE has been the topic of several recent research reports. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Wednesday. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Finally, StockNews.com cut shares of Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Remove Ads

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $146.59 billion, a P/E ratio of 18.36, a PEG ratio of 0.64 and a beta of 0.61. The firm's 50-day moving average price is $26.28 and its 200-day moving average price is $27.18.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the business posted $0.10 earnings per share. The company's revenue for the quarter was up 24.7% on a year-over-year basis. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 0.06% of the company's stock.

Institutional Trading of Pfizer

Institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its position in Pfizer by 0.4% during the fourth quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company's stock valued at $13,756,738,000 after purchasing an additional 2,285,276 shares in the last quarter. State Street Corp raised its stake in Pfizer by 1.2% in the 3rd quarter. State Street Corp now owns 290,460,600 shares of the biopharmaceutical company's stock worth $8,405,930,000 after acquiring an additional 3,405,539 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock worth $4,124,330,000 after acquiring an additional 25,315,159 shares during the period. Geode Capital Management LLC grew its stake in Pfizer by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company's stock valued at $3,190,131,000 after purchasing an additional 2,923,537 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Pfizer in the fourth quarter worth about $2,328,986,000. Institutional investors own 68.36% of the company's stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.